This year’s theme — “Next-Gen Biosafety: Innovations, Insights, and Industry Standards” — brings together leading experts, regulators, and industry scientists for a focused virus safety conference exploring the technologies and strategies shaping the future of biosafety testing, NGS-based virus detection, ATMPs and vaccines.
Join us for a face-to-face full-day event that combines:
- in-depth scientific presentations
- real-world implementation case studies
- high-value networking with peers from biologics, vaccines, ATMPs and plasma-derived products
About the Conference
The 5th Virus Safety Workshop is designed as a single-day conference and networking event for professionals working in:
- virus safety and biosafety testing
- biopharmaceutical development and manufacturing
- vaccines and ATMPs
- regulatory affairs, quality and biosafety strategy
Across one intensive day in Vienna, you’ll receive actionable insights, regulatory perspectives and peer benchmarks you can directly apply in your own virus safety programs.
Event Highlights
Session 1: Regulatory Updates – Virus Safety & Biosafety Standards
Understand the latest developments in virus safety regulations and their impact on biosafety strategies across the biopharmaceutical sector. Learn how evolving guidelines influence study design, validation, and the use of new technologies such as NGS and molecular methods.
Session 2: Next-Generation Sequencing (NGS) in Biosafety Testing
Discover how Next-Generation Sequencing (NGS) is transforming pathogen detection and biosafety testing:
- practical NGS case studies for adventitious agent detection
- integration of NGS into virus safety strategies
- lessons learned from early adopters implementing NGS under GMP
Get a clear view of where NGS can replace or complement traditional in vivo and in vitro assays.
Session 3: Platform Technologies & Continuous Manufacturing
Learn how platform technologies and continuous manufacturing are driving safer, more efficient bioproduction:
- platform-based virus safety strategies
- process validation and viral clearance across multiple products
- how modern biosafety concepts fit into lifecycle and platform approaches
This session is ideal for teams building platform processes or updating their virus safety packages to meet current expectations.
Session 4: ATMPs and Vaccines – Virus Safety in Advanced Modalities
Explore virus safety challenges and best practices for Advanced Therapy Medicinal Products (ATMPs) and vaccines:
- virus safety strategies for gene and cell therapies
- specific considerations for vaccine development and manufacturing
- how to use tools like NGS and high-containment facilities to support innovative products
If you’re working in ATMPs, gene therapy or vaccines, this session will be especially relevant.
Featured Speakers & Experts
Gain insight from distinguished external speakers and ViruSure specialists, including:
- Johannes Blümel (Paul-Ehrlich-Institut, PEI) – Leading authority on virus safety and regulatory science.
- Martin Spruth (AGES – Austrian Agency for Health and Food Safety) – Expert from Austria’s national authority for health, food and pharmaceutical safety.
- Thomas Kreil (Takeda) – Global expert in plasma-derived therapies and viral safety.
- Clara Panosa (HIPRA) – Specialist in vaccine development and biological safety.
- Andy Bailey (CEO, ViruSure) – Co-founder and industry leader in virus safety testing and biosafety strategy.
- Hans-Peter Fasching (ViruSure) – Expert in Next-Generation Sequencing applications for biosafety and adventitious agent detection.
This mix of regulators, industry leaders and CRO specialists makes the 5th Virus Safety Workshop a uniquely practical virus safety conference for decision-makers.